Advancing MASH Diagnostics Through Strategic Partnerships
January 20, 2026 – HistoIndex is set to expand its footprint in clinical hepatology and gastroenterology through new commercial partnerships with leading medical centers in the US and Europe. These collaborations unlock our unique diagnostic offering, which combines standard histopathological evaluation by expert pathologists with AI-driven biopsy analysis.
Such integrated approach will allow clinicians to access NASH-CRN scoring for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis, alongside FibroSIGHT™ Plus (HistoIndex’s AI-based clinical diagnostics solution for quantitative fibrosis assessment) – supporting more consistent, sensitive diagnostics and guiding informed decisions for MASH patients.
Most recently we have announced an important strategic partnership with Houston Research Institute (HRI). Under this agreement, all four HRI medical centres — Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute, and Houston Research Institute Medical Centre — will provide patients with access to HistoIndex’s integrated services. This expands clinical diagnostic availability and supports more precise disease characterization for clinicians and patients alike.
Read our full press release here.
Other Highlights
Scientific poster presentations at San Antonio Breast Cancer Symposium SABCS
Earlier in December 2025, our Senior Clinical Research Manager,Dr Kutbuddin Akbary, presented 2 scientific posters showcasing the use of qFibrosis®-based parameters to identify differences in collagen morphology between receptor-positive and receptor-negative breast cancer biopsies.
Presentation at the MASH-TAG Annual Conference 2026
At this year’s MASH-TAG Annual Conference Dr.Naim Alkhouri, MD, FAASLD presented the latest HistoIndex digital pathology applications for quantitative fibrosis assessment in MASH, further supporting collective efforts toward more precise evaluation in liver disease.
Recent Publications
Our recent publication “Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease” can be found here.
Upcoming Conferences
Don’t miss out – catch us at our upcoming events and conferences:
- EASL Congress 2026 (27-30 May, Barcelona, Spain)
- 2026 06 SOLAR Conference(25-27 June, San Juan, Puerto Rico)
For questions or more information, please contact us at 👉 info@histoindex.com.
📩 More to come in our next edition – stay tuned!